The Department of Justice and Drug Enforcement Administration (DEA) announced that Epidiolex, the newly approved medication by the Food & Drug Administration (FDA), is being placed in schedule V of the Controlled Substances Act (CSA). A schedule V controlled substance is the lowest level, defined as those with a proven medical use and low potential for abuse. Epidolex is a plant-based cannabidiol formulation for the adjunct treatment of seizures associated with two severe forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome, in patients 2 years of age and older.
Certain drugs, substances, and chemicals used to make drugs are classified into five distinct categories or schedules depending upon the drug’s acceptable medical use and the drug’s abuse or dependency potential. The abuse rate is a determinate factor in the scheduling of the drug.
Our Recent Posts
Below is an updated consent for telehealth; you can obtain the official form from my assistant Eric Scott Kincaid. I added in the following (listed a...
Updated Consent for Telehealth
March 24, 2020
I know you’re all closely watching the new developments in the COVID-19 pandemic and I imagine you’ve seen the recent guidelines that sugg...
March 15, 2020
For those folks taking lamotrigine (Lamictal), if your generic brand is Taro Pharmaceuticals, there is a recall (due to inactive ingredients that may...
Recall of specific generic brand of lamotrigine (Lamictal)
January 26, 2020
I'm busy working on my blog posts. Watch this space!